A Study of Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Participants Who Have Experienced CINV(Chemotherapy-Induced Nausea and Vomiting) During the Previous Cycle of Low Emetogenic Chemotherapy (LEC)
- First Posted Date
- 2010-01-22
- Last Posted Date
- 2020-12-23
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT01054456
- Locations
- 🇺🇸
Medical and Surgical Specialists, Galesburg, Illinois, United States
🇺🇸Sheridan Clinical Research, Sunrise, Florida, United States
🇺🇸Trover Center for Clinical Studies; Merle Mahr Cancer Center, Madisonville, Kentucky, United States
To Demonstrate Superiority of Decitabine Over Azacitidine in Subjects With Intermediate- or High-risk MDS.
- First Posted Date
- 2009-11-11
- Last Posted Date
- 2014-10-29
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT01011283
- Locations
- 🇺🇸
Stanford University Cancer Center, Stanford, California, United States
🇺🇸Birmingham Hematology and Oncology Associates, Birmingham, Alabama, United States
🇺🇸Florida Cancer Specialists, Fort Myers, Florida, United States
Pilot Study to Assess Palonosetron Versus Ondansetron as Rescue Medication in Subjects That Develop Postoperative Nausea and Vomiting (PONV) in the Postanesthesia Care Unit (PACU)
- Conditions
- Interventions
- First Posted Date
- 2009-08-28
- Last Posted Date
- 2021-01-11
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 239
- Registration Number
- NCT00967499
- Locations
- 🇺🇸
Precision Trials, Phoenix, Arizona, United States
🇺🇸University of Miami, Miami, Florida, United States
🇺🇸University of Kansas Medical Center, Kansas City, Kansas, United States
A Randomized Study of Epigenetic Priming Using Decitabine With Front Line Induction Chemotherapy Compared With Immediate Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects
- Conditions
- Interventions
- First Posted Date
- 2009-07-22
- Last Posted Date
- 2015-04-13
- Lead Sponsor
- Eisai Inc.
- Registration Number
- NCT00943553
Escalation Study to Determine Bioavailability of a Single Oral Dose of Decitabine in Patients With Myelodysplastic Syndrome (MDS)
- First Posted Date
- 2009-07-17
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT00941109
A 28-Week Open Label Extension Study Evaluating Safety and Tolerability of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment
- Conditions
- Interventions
- First Posted Date
- 2009-07-08
- Last Posted Date
- 2014-01-14
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 145
- Registration Number
- NCT00934375
- Locations
- 🇺🇸
Pahl Pharmaceutical Research, LLC, Oklahoma City, Oklahoma, United States
🇺🇸The University of Texas Mental Sciences Instittute, Houston, Texas, United States
🇺🇸START Center, San Antonio, Texas, United States
Evaluating the Efficacy and Safety of Oral Ranirestat (40 and 80 mg) in Mild to Moderate Diabetic Sensorimotor Polyneuropathy
- Conditions
- Interventions
- First Posted Date
- 2009-06-25
- Last Posted Date
- 2019-02-21
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 800
- Registration Number
- NCT00927914
- Locations
- 🇺🇸
The Johns Hopkins Hospital, Baltimore, Maryland, United States
Once-Daily Oral Avatrombopag Tablets Used in Subjects With Chronic Liver Diseases and Thrombocytopenia Prior to Elective Surgical or Diagnostic Procedures
- Conditions
- Interventions
- First Posted Date
- 2009-06-05
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 130
- Registration Number
- NCT00914927
- Locations
- 🇺🇸
Ochsner Clinic Foundation, New Orleans, Louisiana, United States
Comparing the Efficacy, Safety, and Tolerability of Rabeprazole ER 50 mg With Placebo in Subjects With Symptomatic Gastroesophageal Reflux Disease (sGERD)
- Conditions
- Interventions
- First Posted Date
- 2009-06-02
- Last Posted Date
- 2016-02-02
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 305
- Registration Number
- NCT00911534
A Study to Determine the Metabolism and Elimination of Carbon-14 Labeled Eribulin Acetate (14C-Eribulin) in Patients With Advanced Solid Tumors
- First Posted Date
- 2009-05-27
- Last Posted Date
- 2012-03-09
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT00908908
- Locations
- 🇳🇱
Netherlands Cancer Institute, Amsterdam, Netherlands